TBPH

9.59

1.44% -0.14

Dopo l'orario di chiusura: 9.59

Theravance Biopharma Inc (TBPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$9.73

Aprire:

$9.65

Volume 24 ore:

254.18K

Relative Volume:

1.33

Capitalizzazione di mercato:

$471.58M

Reddito:

$62.02M

Utile/perdita netta:

$-45.65M

Rapporto P/E:

0.8442

EPS:

11.36

Flusso di cassa netto:

$-9.60M

1 W Prestazione:

-2.94%

1M Prestazione:

-3.81%

6M Prestazione:

+10.74%

1 anno Prestazione:

-12.58%

Intervallo 1D:

$9.56

$9.83

Intervallo di 1 settimana:

$9.56

$10.08

Portata 52W:

$7.44

$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Nome

Theravance Biopharma Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

650-808-6000

Indirizzo

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

TBPH's Discussions on Twitter

Confronta TBPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TBPH Theravance Biopharma Inc	9.59	471.58M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-06	Downgrade	Leerink Partners	Outperform → Market Perform
2024-04-12	Iniziato	BTIG Research	Buy
2024-01-08	Downgrade	Evercore ISI	Outperform → In-line
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-11-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-15	Downgrade	JP Morgan	Overweight → Underweight
2021-08-25	Downgrade	Morgan Stanley	Overweight → Underweight
2021-08-24	Downgrade	Cowen	Outperform → Market Perform
2020-10-14	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Iniziato	JP Morgan	Overweight
2020-06-15	Iniziato	Morgan Stanley	Equal-Weight
2020-05-13	Iniziato	Cowen	Outperform
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-06	Aggiornamento	Robert W. Baird	Underperform → Neutral
2019-10-29	Iniziato	H.C. Wainwright	Buy
2018-03-29	Ripresa	Piper Jaffray	Overweight
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-06-16	Iniziato	Cantor Fitzgerald	Overweight
2017-05-11	Reiterato	Needham	Buy
2016-12-21	Iniziato	Needham	Buy
2016-11-03	Iniziato	Piper Jaffray	Overweight
2016-10-12	Downgrade	Robert W. Baird	Neutral → Underperform
2016-08-03	Downgrade	BofA/Merrill	Neutral → Underperform
2016-06-20	Iniziato	Guggenheim	Buy
2016-06-20	Reiterato	Leerink Partners	Outperform
2016-05-12	Iniziato	Leerink Partners	Outperform
2016-05-05	Downgrade	BofA/Merrill	Buy → Neutral
2015-02-03	Aggiornamento	Robert W. Baird	Underperform → Neutral

Mostra tutto

Theravance Biopharma Inc Borsa (TBPH) Ultime notizie

Dec 19, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,372 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Dec 19, 2024

Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Dec 19, 2024

Dec 17, 2024

When (TBPH) Moves Investors should Listen - Stock Traders Daily

Dec 17, 2024

Theravance Biopharma to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 17, 2024

Dec 13, 2024

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? - MSN

Dec 13, 2024

Dec 11, 2024

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail

Dec 10, 2024

Dec 09, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

Dec 09, 2024

Dec 07, 2024

What is Zacks Research's Estimate for TBPH FY2024 Earnings? - MarketBeat

Dec 07, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets - MarketBeat

Dec 07, 2024

Dec 06, 2024

(TBPH) Trading Advice - Stock Traders Daily

Dec 06, 2024

Dec 04, 2024

Theravance Biopharma (STU:0TB) Shares Outstanding (EOP) : 49.17 Mil (As of Sep. 2024) - GuruFocus.com

Dec 04, 2024

Nov 30, 2024

105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC - MarketBeat

Nov 30, 2024

Nov 26, 2024

Trading (TBPH) With Integrated Risk Controls - Stock Traders Daily

Nov 26, 2024

Nov 21, 2024

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Nov 21, 2024

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune

Nov 20, 2024

Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan

Nov 20, 2024

Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com

Nov 14, 2024

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 14, 2024

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada

Nov 13, 2024

Earnings call: Theravance Biopharma reports growth in Q3 2024 - Investing.com

Nov 13, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat

Nov 13, 2024